Lipocine Inc (LPCN): Increasing authorized shares is not a re...

Replies (1) Next 10 Prev Next

LQMTinvestor2018

Send PM Follow Ignore

Followers	12
Posts	2554
Boards Moderated	0
Alias Born	09/13/2017

LQMTinvestor2018

Re: gi197845 post# 772

Monday, 05/16/2022 6:35:13 PM

Monday, May 16, 2022 6:35:13 PM

Increasing authorized shares is not a reverse split ….

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent LPCN News

Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 10:27:25 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:01:22 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 10:33:10 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:05:58 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:40:13 PM
Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:35:13 PM
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression • PR Newswire (US) • 04/02/2026 12:00:00 PM
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 • PR Newswire (US) • 03/10/2026 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 10:13:03 AM
Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 09:05:52 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/26/2026 10:33:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 02:37:58 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 02:35:48 PM
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) • PR Newswire (US) • 02/18/2026 01:00:00 PM
Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 04:49:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 02:31:25 PM
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) • PR Newswire (US) • 01/20/2026 01:00:00 PM
2026 Asset Growth: Why Federal Compliance Is the New Metric • GlobeNewswire Inc. • 01/19/2026 05:20:49 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 09:25:07 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 02:30:22 PM
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) • PR Newswire (US) • 01/12/2026 01:00:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2025 10:09:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/16/2025 02:45:27 PM
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone • PR Newswire (US) • 12/16/2025 01:00:00 PM

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent LPCN News

More LPCN News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent LPCN News

Go Ad-Free